Procaps Group S.A. PROC
Set alert
At close · Mar 12
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 1.01
- Prev close
- 1.01
- Mkt cap
- 297.86M
- Vol
- 652.30K
- Avg vol
- 98.16K
- EPS
- 0.51
- P/E
- 5.18
- Div yield
- 0.00%
More statistics
- Low
- 1.01
- High
- 1.01
- Forward P/E
- 9.78
- Beta
- 0.17
- Short ratio
- 1.08
- Inst. own
- 2.93%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 24, 2024
- 50-d avg
- 1.76
- 200-d avg
- 2.30
- 1y target
- 0.00
News
1 week ago gurufocus.com
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026PR NewswireINDI
2 weeks ago gurufocus.com
/C O R R E C T I O N - AbbVie/
/C O R R E C T I O N - AbbVie/PR NewswireNORTH CHICAGO, Ill., Oct. 18, 2026In the news release, AbbVie to Present Data at the 2026 European Society for Medical
2 weeks ago gurufocus.com
Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress
Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) CongressPR NewswireINDIANAPOLIS, Oct. 18, 2026F
2 weeks ago gurufocus.com
AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio
AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor PortfolioPR News
1 month ago gurufocus.com
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced results from Part C of the Phase 1/2 RAINFOLâ¢-01 trial evaluating rinatabart sesutecan (Rina-S), an inv
12 months ago defenseworld.net
ProCook Group (LON:PROC) Trading Up 5.9% – Should You Buy?
ProCook Group plc (LON: PROC - Get Free Report)'s share price was up 5.9% on Wednesday. The company traded as high as GBX 36 and last traded at GBX 36. Approximately 58 shares changed hands during…
1 year ago globenewswire.com
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject…
1 year ago globenewswire.com
Procaps Group Secures $130 Million in Equity Investment and Completes Comprehensive Debt Restructuring, as New Investors Take Over Strategic Leadership
New Investors Take Over the Strategic Leadership as Headquarters Move to Bogotá, Marking the Start of a New Chapter of Growth, Execution, and Transformation under Enhanced Governance
1 year ago seekingalpha.com
Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release
Corcept Therapeutics Incorporated's relacorilant met the primary endpoint in the phase 3 ROSELLA study for platinum-resistant ovarian cancer patients, boosting shares by over 90% the very same day.…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
1 year ago globenewswire.com
Procaps Group Receives Delisting Notice From Nasdaq
MIAMI and BARRANQUILLA, Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services…
1 year ago globenewswire.com
Procaps Group Receives Additional Delinquency Letter
MIAMI and BARRANQUILLA, Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
1 year ago globenewswire.com
Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates
MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services…
1 year ago globenewswire.com
Procaps Group Announces Financing, Shareholders Agreement and Board Updates
MIAMI and BARRANQUILLA, Colombia , Dec. 03, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services…
-
1 year ago benzinga.com
Why Poseida Therapeutics Shares Are Trading Higher By 219%; Here Are 20 Stocks Moving Premarket
Why Poseida Therapeutics Shares Are Trading Higher By 219%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
1 year ago benzinga.com
Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
1 year ago globenewswire.com
Procaps Receives Nasdaq Listing Determination; To Request Hearing and Further Stay Pending Hearing
MIAMI and BARRANQUILLA, Colombia, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), announced today that, on November 13, 2024, the Company received…
2 years ago globenewswire.com
Procaps Issues Shareholder Letter Update
MIAMI and BARRANQUILLA, Colombia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services,…
2 years ago globenewswire.com
Procaps Issues Shareholder Letter Update
MIAMI and BARRANQUILLA, Colombia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical…
2 years ago globenewswire.com
Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024
COPENHAGEN, Denmark, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced initial data showing signs of clinical activity in heavily pre-treated patients with…
2 years ago globenewswire.com
Procaps Issues Shareholder Letter
MIAMI and BARRANQUILLA, Colombia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical…
2 years ago investorplace.com
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.
2 years ago https://www.accesswire.com
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and…
-
2 years ago benzinga.com
Earnings Scheduled For November 14, 2023
Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.
-
2 years ago benzinga.com
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge…
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday saw 132 companies set new 52-week lows.
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
-
3 years ago benzinga.com
Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session.
-
3 years ago benzinga.com
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.